ArticleDiscover oncology2025
Unveiling the anticancer potential of flavonoids in hepatocellular carcinoma through microbiome and spatially resolved metabolomics analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dietary polyphenols maintain human health through modulation of gut microbiota.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) causes a large worldwide health burden, needing novel ways to prevention and treatment. Traditional Chinese medicine, which is rich in bioactive substances, has emerged as a viable approach to tackling HCC difficulties. Artemisia rupestris L. (AR), a perennial plant, has received interest for its immunoregulatory qualities and potential protection against viral influenza and hepatocellular cancer.
methodsIn this work, we looked at the pharmacological effects of Artemisia rupestris L. extract (ARE) on HCC mice. We used 16 S rRNA sequencing and computational biology approaches to investigate ARE-induced changes in bacterial composition inside HCC mouse tissues. Furthermore, we used liquid chromatography tandem mass spectrometry (UPLC-MS/MS) to identify metabolic changes caused by ARE.
resultsOur data indicate that ARE affects hepatocellular cancer via several pathways. AR offers a multi-faceted strategy to combating HCC by influencing critical metabolic pathways such α-linolenic acid and glycerophospholipid metabolism.
conclusionsThis research sheds new light on Artemisia rupestris L.'s anticancer potential, setting the platform for a more in-depth knowledge of its influence on hepatocellular carcinoma using a multi-omics approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.